Rs 80 crore investment in ImmunoACT to be infused by Laurus Labs
Indian multinational pharmaceutical and biotechnology company Laurus Labs has invested Rs 80 crore in Immunoadoptive Cell Therapy Private Ltd (lmmunoACT). ImmunoACT is developing an affordable CAR T-cell therapy for curing specific types of blood cancers.
Laurus will get an additional stake of 7.24 percent in ImmunoACT, as part of Series-B funding.